2-氨基-6-[(1R,2R)-1,2,3-三羟基丙基]-4(1H)-蝶啶酮 | 10162-32-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 中文名称: 2-氨基-6-[(1R,2R)-1,2,3-三羟基丙基]-4(1H)-蝶啶酮
• 英文名称: (-)-2-amino-4(3H)-oxo-6-[(1R,2R)-1,2,3-trihydroxypropyl]pteridine
• 英文别名: 2-amino-6-[(1R,2R)-1,2,3-trihydroxypropyl]pteridin-4(3H)-one；Umanopterin；monapterin；D-monapterin；2-amino-6-(1,2,3-trihydroxy-propyl)-3H-pteridin-4-one；2-amino-6-((1R,2R)-1,2,3-trihydroxy-propyl)-3H-pteridin-4-one；D-Monapterin；2-amino-6-[(1R,2R)-1,2,3-trihydroxypropyl]-3H-pteridin-4-one
• CAS: 10162-32-0
• 化学式: C₉H₁₁N₅O₄
• 分子量: 253.217
• InChiKey: BMQYVXCPAOLZOK-INEUFUBQSA-N

物化性质

• 沸点：
  590.4±60.0 °C(Predicted)
• 密度：
  2.02±0.1 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  154
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 2-氨基-6-[(1R,2R)-1,2,3-三羟基丙基]-4(1H)-蝶啶酮 反应 0.67h， 生成 Acetic acid (1R,2R)-2,3-diacetoxy-1-(2-acetylamino-4-oxo-3,4-dihydro-pteridin-6-yl)-propyl ester
  参考文献：
  名称：

  Occurrence of umanopterin, a new diastereomer of neopterin, in urine from cancer patients

  摘要：

  A new pteridine compound, named umanopterin, was isolated from urine of cancer patients. The structure was confirmed to be 2-amino-4-hydroxy-6-[(1'R,2' R)-1',2',3'-trihydroxypropyl]-pteridine, a diastereomer of neopterin.

  DOI：

  10.1016/s0040-4039(00)91617-4
• 作为产物：
  描述：

  6-羟基-2,4,5-三氨基嘧啶 、 D-木糖 在 sodium acetate 、 硼酸 、 一水合肼 作用下， 生成 2-氨基-6-[(1R,2R)-1,2,3-三羟基丙基]-4(1H)-蝶啶酮
  参考文献：
  名称：

  The Synthesis of Some 2-Amino-4-hydroxy-6-polyhydroxyalkyl-pteridines Which Are Active in Supporting the Growth of the Protozoön Crithidia fasciculata

  摘要：

  DOI：

  10.1021/ja01541a062

文献信息

• [EN] PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS<br/>[FR] PEPTIDOMIMÉTIQUES POUR LE TRAITEMENT D'INFECTIONS PAR CORONAVIRUS ET PICORNAVIRUS
  申请人：UNIV EMORY

  公开号：WO2020247665A1

  公开（公告）日：2020-12-10

  Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV- 2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

  用于预防、治疗或治愈人类主体或其他动物宿主中的冠状病毒、小RNA病毒和/或肝炎病毒感染的化合物、组合物和方法。可治疗的特定病毒包括肠病毒。在一个实施例中，这些化合物可用于治疗严重急性呼吸综合征病毒感染，如人类冠状病毒229E、SARS、MERS、SARS-CoV-1（OC43）和SARS-CoV-2。在另一个实施例中，这些方法用于治疗患有两种或更多这些病毒的患者，或一种或多种这些病毒与诺如病毒的组合。
• [EN] HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA GTP CYCLOHYDROLASE 1 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：HERCULES TECHNOLOGY MAN CO V INC

  公开号：WO2011035009A1

  公开（公告）日：2011-03-24

  The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

  本发明涉及小分子杂环抑制剂对GTP环化酶（GCH-I）的，或其互变异构体、前药或药用可接受盐。该发明还涉及这些化合物的药物组合物以及这些化合物用于治疗或预防疼痛（例如炎症性疼痛、伤害性疼痛、功能性疼痛或神经病理性疼痛）的医疗用途。
• METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS
  申请人：GRIFFITH UNIVERSITY

  公开号：US20210069180A1

  公开（公告）日：2021-03-11

  In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

  在一个方面，该发明涉及一种治疗方法，所述方法选自以下组合：(a)治疗被识别或诊断为患有肌无力性脑脊髓炎/慢性疲劳综合征（ME/CFS）的受试者的症状，例如疼痛；(b)治疗具有TRPM3离子通道活性异常的受试者的症状，例如疼痛；(c)恢复具有TRPM3离子通道活性异常的受试者的NK细胞功能；以及(d)恢复具有TRPM3离子通道活性异常的受试者的钙稳态。该方法包括向受试者施用来自以下组合的至少一种治疗化合物的治疗有效量的步骤：(i)阿片受体拮抗剂；(ii)阿片拮抗剂；以及(iii)恢复TRPM3离子通道活性的治疗化合物。在某些实施例中，治疗化合物是盐酸纳曲酮。
• Cytotoxic agents and methods of use
  申请人：Xiao Xiao-Yi

  公开号：US20050203162A1

  公开（公告）日：2005-09-15

  Disclosed are compounds that inhibit proteasomic activity in cells. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly cell proliferative conditions, such as cancer and inflammatory conditions.

  揭示了一种抑制细胞中蛋白酶体活性的化合物。还揭示了包含这些化合物的药物组合物，以及治疗疾病的方法，特别是细胞增殖性疾病，如癌症和炎症性疾病。
• [EN] POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À DES EXCIPIENTS POLYMÉRIQUES HYPERBRANCHÉS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013024048A1

  公开（公告）日：2013-02-21

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I),wherein POL is a polymeric moiety,each Hyp is independently a hyperbranched moiety,each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water- soluble carrier-linked prodrugs and methods of treatment.

  本发明涉及水溶性载体连接的前药，其化学式为（I），其中POL是聚合物基团，每个Hyp是独立的超支化基团，每个基团SP是独立的间隔基团，每个L是独立的可逆前药连接基团，m为0或1，每个n是独立的整数，范围从2到200，每个x是独立的0或1。此外，还涉及包含所述水溶性载体连接的前药的药物组合物和治疗方法。